CervoMed Inc.
CRVO
$8.28
$0.060.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -38.81% | -19.44% | 15.14% | 36.29% | 116.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -38.81% | -19.44% | 15.14% | 36.29% | 116.29% |
| Cost of Revenue | 58.39% | 97.25% | 179.07% | 190.09% | 263.68% |
| Gross Profit | -275.82% | -810.08% | -1,947.79% | -1,463.07% | -793.67% |
| SG&A Expenses | 14.77% | 11.02% | 23.22% | 40.61% | 80.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.77% | 58.50% | 77.22% | 86.96% | 115.40% |
| Operating Income | -102.01% | -128.52% | -133.09% | -133.29% | -114.74% |
| Income Before Tax | -114.15% | -348.36% | -349.69% | -650.10% | -793.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -114.15% | -348.36% | -349.69% | -650.10% | -793.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.15% | -348.36% | -349.69% | -650.10% | -793.71% |
| EBIT | -102.01% | -128.52% | -133.09% | -133.29% | -114.74% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -79.55% | -543.67% | 25.67% | 43.29% | 73.74% |
| Normalized Basic EPS | -79.53% | -543.45% | 25.67% | 43.29% | 73.74% |
| EPS Diluted | -79.55% | -47.46% | 49.33% | 59.03% | 78.50% |
| Normalized Diluted EPS | -79.53% | -437.42% | 27.65% | 44.54% | 74.08% |
| Average Basic Shares Outstanding | 19.32% | 43.40% | 114.02% | 204.13% | 513.80% |
| Average Diluted Shares Outstanding | 19.32% | 40.76% | 108.16% | 191.54% | 460.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |